Intensive Care Management of Severe Tetanus

Area of Science:

• Neurology
• Infectious Diseases
• Critical Care Medicine

Background:

• Tetanus results from tetanospasmin exotoxin produced by *Clostridium tetani*.
• This toxin inhibits gamma-aminobutyric acid (GABA) neurotransmission, causing severe muscle rigidity and spasms.
• Manifestations include trismus, dysphagia, opisthotonos, and potentially life-threatening autonomic dysfunction.

Purpose of the Study:

• To outline the intensive care management strategies for severe tetanus.
• To highlight the critical interventions required to mitigate complications and reduce mortality.

Main Methods:

• Review of clinical presentation and pathophysiology of tetanus.
• Description of pharmacological interventions including antibiotics, tetanus immune globulin, benzodiazepines, and neuromuscular blockers.
• Discussion of supportive care measures such as mechanical ventilation, tracheostomy, and nutritional support.

Main Results:

• Effective management requires a multi-faceted approach addressing toxin neutralization, muscle spasm control, and autonomic instability.
• Early tracheostomy and benzodiazepine administration (e.g., diazepam) are crucial for managing respiratory and autonomic symptoms.
• Mortality rates for severe tetanus range significantly from 5% to 50%.

Conclusions:

• Intensive care management of severe tetanus focuses on preventing complications like apnea and rhabdomyolysis.
• Prompt and aggressive supportive care, including respiratory and autonomic support, is essential for improving outcomes.
• Dysautonomia management remains challenging and is a key determinant of patient mortality.